The €2.1m investment was led by Furthr VC, Atlantic Bridge and HBAN MedTech Syndicate, with Enterprise Ireland and other private investors also investing.
It aims to address a critical gap in the availability and accuracy of current technologies used to detect seizures in newborns admitted to the neonatal intensive care unit . Its new technology allows routine monitoring of babies across various hospital settings without the need for specialised expertise and it also eliminates the need for extensive training in both configuration and result interpretation.
Dr Mark O'Sullivan, co-founder and chief executive of NeuroBell, said today's funding marks a significant leap forward in advancing its goal to launch the product and get it into the hands of clinicians around the world to help newborn patients.